Submitted by Anonymous (not verified) on 16 June 2025 - 13:29
Opinion/decision on a Paediatric investigation plan (PIP): Zynlonta, Loncastuximab tesirine, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: P/0152/2024
Source: